Current Health is a technology company.
Current Health has raised $83.1M across 8 funding rounds.
Current Health has raised $83.1M in total across 8 funding rounds.
Current Health has raised $83.1M in total across 8 funding rounds.
Current Health's investors include Helium-3 Ventures, MMC Ventures, Northpond Ventures, Platanus Ventures, Presight Capital, Section 32, Valar Ventures, Christian Woolfenden, Matt Bellamy, Richard Fearn, Par Equity.
Current Health is a healthcare technology company that provides an enterprise clinical operating system for delivering high-acuity care safely and scalably in home and community settings.[1][3][5] Its platform combines a proprietary FDA-cleared wearable for continuous vital sign monitoring, third-party devices, telehealth, patient engagement tools, and EHR integrations to support programs like Hospital at Home, advanced therapies (e.g., CAR-T), post-discharge care, and chronic disease management.[2][5][6] The company serves healthcare providers, health systems, and biopharma companies, solving the challenges of shifting complex care from hospitals to lower-cost settings while maintaining clinical quality, reducing provider burden, and improving patient outcomes and financial results.[1][3][7] With 51-200 employees based in California, Current Health has demonstrated growth through partnerships with over 50 health systems worldwide, including major expansions like Mass General Brigham's Home Hospital program serving 70+ patients.[7][8]
Current Health was co-founded by Christopher McGhee, inspired by his grandmother's unnecessary extended hospital stay for a condition that could have been managed at home with proper support.[3] This personal experience sparked the mission to enable hospitals to deliver hospital-level care beyond their walls.[3] The company originated as a remote patient monitoring (RPM) platform and gained early traction through FDA-cleared technology for vital sign monitoring and alarming.[2][6] In 2021, it expanded under the backing of Best Buy Health, a major U.S. technology leader, integrating with programs like Geisinger's ConnectedCare365 for chronic care.[3][4] By 2025, former CEO Christopher McGhee led a buyback, returning the company to independence to refocus on scrappy innovation, patient safety, and customer needs amid evolving AI and care-at-home demands.[3][4][9]
Current Health stands out in the care-at-home space through purpose-built technology and operational support tailored for real-world complexity:
Current Health rides the Hospital at Home and care-at-home trend, accelerated by post-pandemic shifts to reduce inpatient strain, lower costs, and improve outcomes amid workforce shortages and rising chronic disease prevalence.[1][8] Timing is ideal as CMS expansions and payer incentives favor lower-cost, high-margin settings, with Hospital at Home proven to cut complications and boost recovery.[8] Market forces like EHR interoperability mandates and AI advancements enable seamless scaling, positioning Current Health to influence ecosystem-wide adoption by providing turnkey infrastructure that health systems trust for complex care.[3][6][9] Its independence in 2025 allows agile responses to these dynamics, bridging providers and biopharma for therapies like CAR-T in outpatient/home environments.[1][4]
Current Health is poised for accelerated growth as an independent player, emphasizing rapid product innovation, AI-driven automation, and expanded health monitoring services to scale care-at-home cost-efficiently.[9] CEO McGhee's priorities—enhancing clinical teams, leveraging AI for frontline efficiency, and recapturing startup agility—align with a maturing market where AI transforms remote care delivery.[9] Influence may evolve through deeper AI-alarm integrations, broader chronic care ecosystems, and global expansions, solidifying its role in making high-acuity home care standard. This return to roots echoes its origin in personal necessity, now amplified by technology to transform healthcare accessibility.[3][9]
Current Health has raised $83.1M across 8 funding rounds. Most recently, it raised $43.0M Series B in April 2021.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Apr 1, 2021 | $43.0M Series B | Helium-3 Ventures, MMC Ventures, Northpond Ventures, Platanus Ventures, Presight Capital, Section 32, Valar Ventures, Christian Woolfenden, Matt Bellamy, Richard Fearn | |
| Jun 1, 2020 | $4.0M Series A | Par Equity | |
| Dec 1, 2019 | $12.0M Series A | Par Equity | |
| Nov 1, 2019 | $12.0M Venture Round | Par Equity | |
| Jul 1, 2018 | $7.0M Venture Round | Par Equity | |
| Dec 1, 2017 | $57K Venture Round | Par Equity | |
| Apr 1, 2017 | $3.0M Seed | Par Equity | |
| Oct 1, 2016 | $2.0M Seed | Par Equity |